AMPK-activation by Metformin in FSGS: AMP-FSGS
Part of paid clinical trials in New Haven, Connecticut.
- Sponsor
- Yale University
- Study ID
- NCT06090227
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Focal Segmental Glomerulosclerosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Metformin + Standard of Care — DRUGAdministration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.
- Placebo + Standard of Care — OTHERAdministration of daily placebo tablets with standard of care for 6 months.
Study Details
The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).
Key Dates
- Start date
- Dec 14, 2023
- Status verified
- Jan 2026
- Primary completion
- Nov 30, 2027
- Completion
- Nov 30, 2027
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Metformin + Standard of CareAdministration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.
- Placebo Comparator: Placebo + Standard of CareAdministration of daily placebo tablets with standard of care for 6 months.
Primary Outcome Measure
Slope of urinary NPHS2:Creatinine ratio [ Time Frame: 6 months following randomization ]
Central Contacts
- Madhav C Menon, MD20373734507
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Yale New Haven Hospital | New Haven | Connecticut | 06510 | Madhav Menon Francis P Wilson, MD (SUB_INVESTIGATOR) Randy Luciano, MD PhD (SUB_INVESTIGATOR) |
| Mount Sinai Hospital | New York | New York | 10029 | Cijiang He Joji Tokita (SUB_INVESTIGATOR) Kristin Meliambro (SUB_INVESTIGATOR) Jia Fu (SUB_INVESTIGATOR) |
Find similar trials in New Haven, CT
Related Studies
- Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in ChildrenRecruiting · Kaneka Medical America LLC · Loma Linda, California
- Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 SystemRecruiting · Kaneka Medical America LLC · Loma Linda, California
- NEPTUNE Match StudyRecruiting · University of Michigan · Atlanta, Georgia
- Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesPHASE2 · Recruiting · Travere Therapeutics, Inc. · Los Angeles, California